BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:57 PM
 | 
Jun 11, 2010
 |  BC Extra  |  Clinical News

Trial shows dabigatran non-inferior to Lovenox

Boehringer Ingelheim GmbH (Ingelheim, Germany) said dabigatran was non-inferior to Lovenox enoxaparin on the composite primary endpoint in the Phase III RE-NOVATE trial to prevent venous thromboembolism (VTE) following total hip...

Read the full 145 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >